Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized crossover phase 3 study of an oral hypomethylating agent, ASTX727 (DEC-C), compared to IV Decitabine in AML patients
By downloading this material, you acknowledge that this action may be considered a transfer of value and will be reported by Taiho Oncology, Inc. in accordance with applicable Transparency and Sunshine Act requirements.